Krystal Biotech (KRYS) Financials

$358.24

$-13.23 (-3.56%)

As on 04-Sep-2026 16:00EDT

Market cap

$10,603 Mln

Revenue (TTM)

$440 Mln

P/E Ratio

44.9

P/B Ratio

8.1

Div. Yield

0 %

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Operating Revenue	440.48	389.13	290.52	50.70	--	--
Cost of Revenue	29.34	28.77	20.06	3.09	4.06	2.77
Gross Profit	411.14	360.36	270.45	47.61	-4.06	-2.77
Operating Expenses	213.23	199.06	204.76	157.33	145.20	68.28
Operating Profit (EBIT)	197.92	161.30	65.70	-109.73	-145.20	-68.28
Other Income	--	--	--	--	--	--
Profit before Tax	226.62	189.47	95.36	12.90	-139.98	-69.57
Provision for Tax	-14.85	-15.36	6.20	1.97	34.05	2.73
Profit after Tax (Net Income)	241.47	204.83	89.16	10.93	-139.98	-69.57
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-139.98	-69.57

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Shareholder's Funds	1,359.13	1,219.56	946.38	778.64	522.23	593.58
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	14.13	11.29	7.46	6.62	7.37	6.98
Current Liabilities	127.40	102.94	102.00	33.09	28.85	25.74
Total Liabilities	1,628.05	1,333.79	1,055.84	818.36	558.45	626.30

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Non-Current Assets	441.00	309.19	313.79	230.45	174.67	184.03
Current Assets	1,059.65	1,024.60	742.05	587.91	383.78	442.27
Total Assets	1,628.05	1,333.79	1,055.84	818.36	558.45	626.30
Total Debt*	8.85	9.34	7.26	8.09	8.93	8.02
Net Current Assets	932.25	921.66	640.05	554.82	354.93	416.53

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Cash From Operating Activities	--	200.87	123.42	-88.80	-100.57	-47.94
Cash Flow from Investing Activities	--	-58.42	-163.44	82.64	-114.08	-226.77
Cash from Financing Activities	--	8.71	27.01	202.75	35.35	347.69
Net Cash Inflow / Outflow	--	--	--	--	--	72.98

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Adjusted EPS ($)	8.00	6.84	2.98	0.38	-5.48	-3.13
Cash EPS ($)	7.98	7.06	3.21	0.55	-5.32	-3.01
Adjusted Book Value ($)	45.92	40.72	31.67	27.02	20.44	26.73
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	6.71	4.13	-3.08	-3.94	-2.16
Free Cash Flow per Share ($)	--	6.31	3.99	-3.49	-6.01	-5.24

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
ROCE (%)	--	18.77	10.25	1.66	-24.71	-15.37
ROE (%)	18.73	18.91	10.34	1.68	-25.09	-15.71
ROA (%)	16.93	17.14	9.51	1.59	-23.63	-14.85
EBIT Margin (%)	33.43	48.69	35.52	-191.77	--	--
Net Margin (%)	54.82	52.64	30.69	21.56	--	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Revenue Growth (%)	22.63	0.34	4.73	--	--	--
EBIT Growth (%)	-15.33	83.60	206.14	19.11	-76.56	-111.64
Net Profit Growth (%)	64.57	129.74	715.58	107.81	-101.20	-116.28
EPS Growth (%)	62.67	1.29	6.87	1.07	-0.75	-0.95
Book Value Growth (%)	26.74	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Price / Earnings	44.89	36.05	52.51	327.03	-14.46	-22.33
Price / Book Value	8.09	6.05	4.95	4.59	3.88	2.62
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	49.70	33.49	37.22	-33.41	-14.16	-16.96
Close Price ($)	371.67	246.54	156.66	124.06	79.22	69.95
High Price ($)	382.54	265.92	219.34	132.68	85.11	102.99
Low Price ($)	130.50	122.80	107.50	69.81	47.67	38.86
Market Cap ($ Cr)	10,603.49	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debt to Equity	--	0.01	0.01	0.01	0.02	0.01
Short term debt to equity ratio	0.00	0.00	0.00	0.00	0.00	0.00
Current Ratio	8.32	9.95	7.28	17.76	13.30	17.18
Quick Ratio	7.96	9.56	7.02	17.55	13.30	--
Interest Coverage	--	--	--	--	-23.02	-45.63

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debtors to sales (%)	31.48	32.75	36.06	82.92	--	--
Asset Turnover	0.31	0.33	0.31	0.07	--	--
Receivable days	--	108.96	92.27	151.43	--	--
Inventory Days	--	425.15	304.90	412.29	--	--
Payable days	--	52.19	62.21	344.12	557.51	692.71
Cash Conversion Cycle	--	481.92	334.96	219.61	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Income Statement ($ Mln)